Market Overview

UPDATE: Investors Bullish On InterMune After Leerink Upgrade

Related ITMN
What You Need to Know About the Roche-InterMune Deal
Markets Reverse Early Morning Losses; Still Lower On The Day

In a report issued Monday, Leerink upgraded its rating of InterMune (NASDAQ: ITMN) from Market Perform to Outperform with a target price of $41.

Howard Liang of Leerink anticipates that recent developments in trials done by InterMune should provide the company with plenty of upside. Esbriet particularly is one of the drugs that much of InterMune's success will hinge on, based on Liang's views.

Investors have been extremely bullish on InterMune as it is surging in Monday's session up 14.5 percent to $39.30 at last check.

Latest Ratings for ITMN

Aug 2014UBSDowngradesBuyNeutral
Aug 2014Cowen & Co.Initiates Coverage onMarket Perform
Aug 2014JMP SecuritiesDowngradesMarket OutperformMarket Perform

View More Analyst Ratings for ITMN
View the Latest Analyst Ratings

Posted-In: Howard Liang LeerinkAnalyst Color News Upgrades Analyst Ratings Movers


Related Articles (ITMN)

View Comments and Join the Discussion!